F552 in Louisiana. Pick another state for the same tag.
Against expectation — 2025
Louisiana cites F552 less often than its own record predicts
Versus expected share0.44×
0.44 times the national share — cited less often here than elsewhere.
Share of Louisiana citations0.24%
Of every deficiency written in Louisiana in 2025, this is the portion that was F552.
Louisiana0.24%
National0.54%
Share of all citations that were F552.
Each state is measured against its own expected share, not against other states.
In the surveyor’s words
What Louisiana surveyors wrote
F552 findings written in Louisiana, one from each severity band recorded here, most serious first.
Severity is as the surveyor wrote it. Some findings had already been corrected before the survey.
E · No harm, potential for more than minimal, patternAugust 19, 2026
Based on interview and record reviews, the facility failed to provide informed consents for psychotropic medications to residents and/or their representatives for 4 (Resident #19, Resident #56, Resident #83, Resident #87) of 5 sampled residents reviewed for unnecessary medications. Findings:
Review of the facility's undated Informed Consent for Psychotropic Drugs policy revealed, in part, a psychotropic medication was any drug that affected brain activities associated with mental processes and behavior, including but not limited to antipsychotics, antidepressants, anxiolytics, hypnotics, mood stabilizers, anticonvulsants, central nervous system agents, muscle relaxants, anticholinergics, and antihistamines. …
Deficiency Index is independent and is not affiliated with, endorsed by, or approved by CMS, Medicare, or any government agency. About this data · Report a correction